IMRX Stock Analysis: Buy, Sell, or Hold?
IMRX - Immuneering Corporation Class A Common Stock
$5.19
0.14 (2.77%)
▲
5d:
+14.57%
30d:
+21.26%
90d:
-2.63%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When IMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMRX is currently trading at $5.19, which is considered extended relative to its 30-day fair value range of $4.12 to $5.06.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.00 (+227.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.00 (+227.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.12 -
$5.06
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 227.6% below Wall St target ($17.00)
Trading Range Analysis
30-Day Trading Range
$4.12 -
$5.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.26
Resistance Level
$5.22
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.88
Wall Street Target
$17.00
(+227.6%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: July 02, 2026 10:44 PM ET
Data refreshes hourly during market hours. Next update: 11:44 PM
Data refreshes hourly during market hours. Next update: 11:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Harold Eugene Brakewood
BUY
5250 shares
2026-01-16
Brett Matthew Hall
BUY
2298 shares
2026-01-15
Thomas J Schall
BUY
21645 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$291 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 61 BUY |
